- US500 and US100 slightly lose at the beginning of the session
- US Dollar (USD) one of the stronger currencies today
- US bond yields fall to 4.20%
The last day on Wall Street starts in the red. Indexes lose slightly at the opening of the cash session, but it should be noted that the quotations are currently at historical highs. The weaker sentiment in the stock market is also supported by the strengthening dollar. USD gains by 0.3%, and in most currency pairs between 0.3-0.4%, and even up to 0.6% in the case of NZD, AUD, and SEK. Meanwhile, yields on 10-year US bonds lose from the level of 4.21%.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appUSDIDX index gains over 0.30% and is approaching the key zone around 104,000. This is the second strong session in a row for the dollar, which is starting to exert stronger pressure on the stock market. Source: xStation 5
US500
The US500 index has been moving very dynamically upwards in recent weeks. Along the way, practically since the beginning of 2024, we have not experienced any significant correction. Looking at the chart, one can notice an almost parabolic upward movement. A correction in the indexes would be justified at this moment. However, looking at the market behavior, which finds reasons for growth in each publication, such a correction is hard to predict unequivocally.
Source: xStation 5
Company News
FedEx (FDX.US) gains as much as 8.70% despite mixed results in Fiscal Quarter 3 (FQ3) and a narrowed outlook for Fiscal Year 2024. This surge was attributed to cost-cutting in its Express business and improved margins in FQ3. The Express segment outperformed expectations with a 2.5% operating margin. The company’s overall adjusted operating margin increased to 6.2%. FedEx revised its FY2024 profit guidance to $17.25 - $18.25 per share and announced a new $5 billion share repurchase program.
Ocugen (OCGN.US) gains as much as 17% after a federal appeals court ruling that upheld a lower court's decision against shareholders' claims. These shareholders had accused the biotech company of misleading investors regarding its COVID-19 vaccine, Covaxin, specifically about obtaining emergency-use authorization from the U.S. Food and Drug Administration. The U.S. Court of Appeals for the Third Circuit rejected these claims, stating that the investors couldn't prove any point where Ocugen misrepresented its engagement with the FDA. The court emphasized that all relevant details were accessible to any reasonable investor.
Nike (NKE.US) shares fell by 8% following a revenue outlook that projected minimal growth. Despite exceeding FQ3 earnings expectations, Nike forecasted about 1% growth in FY2024 revenue and a low single-digit decline in the first half of fiscal 2025, mainly due to challenges in overseas markets.
Lululemon Athletica (LULU): dips over 18% after announcing a first-quarter outlook that was below market expectations. The company projected Q1 revenue of $2.18B - $2.20B and EPS of $2.35 - $2.40, both below consensus estimates. The full-year revenue expectation was set at $10.7B - $10.8B, slightly below the consensus.
Reddit (RDDT.US) shares fell by 8% following their debut, which had initially seen a 48% surge. The stock quotations showed strong initial performance, but the decline followed on the subsequent trading day.
Tesla (TSLA.US) shares declined by 3% amid reports of the company reducing electric car production at its China plant due to slowing EV sales growth.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
